Results 71 to 80 of about 2,626 (203)

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Modern treatment methods in atopic dermatitis - literature overview

Journal of Education, Health and Sport
Introduction and aim: Atopic dermatitis (AD) is a chronic inflammatory skin disease. It is characterised by periods of exacerbation and remission of symptoms such as pruritus, dry skin and eczematous lesions with characteristic morphology.
Martyna Borowska-Łygan, Jakub Tomaszewski, Wojciech Urban, Konrad Strużek, Jan Biłogras, Kornelia Karamus, Rafał Wojciech Rejmak   +6 more
doaj   +1 more source

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

BMC Pulmonary Medicine, 2019
Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2.
Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice   +6 more
doaj   +1 more source

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report

SAGE Open Medical Case Reports, 2023
A patient presented to clinic with atopic dermatitis that had been previously unresponsive to multiple topical and systemic therapies. They were successfully treated with a combination of tralokinumab and upadacitinib, showing significant improvement ...
Rafael Paolo Lansang, Irene X Zhao, Perla Lansang   +2 more
doaj   +1 more source

[Pharmacoeconomic Comparison Between Dupilumab and Tralokinumab for the Treatment of Atopic Dermatitis in Italy: A Cost-per-Responder Analysis] [PDF]

OBJECTIVE: A cost-per-responder model was developed to compare the pharmacoeconomic value of dupilumab and tralokinumab, in combination with topical corticosteroids (TCS), for treating atopic dermatitis (AD) in Italy.METHODS: An indirect treatment ...
Gisondi, Paolo, Chiricozzi, Andrea, Pani, Marcello, Povero, Massimiliano, Castello, Luca, Pedone, Maria Paola, Noonan, Kerry, Wang, Zhixiao, Di Turi, Roberta   +8 more
core   +2 more sources

Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities [PDF]

, 2014
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The two main forms of IBD are Crohn's disease and ulcerative colitis. According to the recent concept the disease is caused by a combination
Gyires, Klára, Tóth, Viktória, Zádori, Zoltán Sándor   +2 more
core   +1 more source

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1350-1361, May 2026.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Frontiers of antifibrotic therapy in systemic sclerosis [PDF]

, 2017
Although fibrosis is becoming increasingly recognized as a major cause of morbidity and mortality in modern societies, targeted anti-fibrotic therapies are still not approved for most fibrotic disorders. However, intense research over the last decade has
Abraham, DJ, Asano, Y, Distler, JH, Distler, O, Feghali-Bostwick, C, Soare, A   +5 more
core  

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

Aging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu, Ming Yang, Fugang Xiao, Jinrong Zeng   +3 more
wiley   +1 more source

Dupilumab in patients with bullous pemphigoid and concomitant atopy

Frontiers in Pharmacology
BackgroundBullous pemphigoid (BP) and atopic dermatitis (AD) are chronic inflammatory skin diseases that may share overlapping immunopathogenic mechanisms, particularly a type 2 immune response.
Katerina Jobst, Stephan R. Künzel, Stephan R. Künzel, Stefan Beissert, Susanne Abraham   +4 more
doaj   +1 more source